THINC
Treg/Th17-Related Cytokine Profile and Systemic Inflammatory Indices in Differentiated Thyroid Cancer: Relationship With Clinicopathological Features
Sponsor study identifier
observational
90
1 country
1
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
August 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study measures circulating immune-signalling molecules before thyroid surgery to determine whether they differ between patients whose thyroid nodule proves to be a differentiated thyroid carcinoma and patients whose nodule proves to be benign. Adults scheduled for elective thyroidectomy for a thyroid nodule or nodular goiter are enrolled consecutively before surgery, while the nature of the nodule is still unknown. One additional blood tube is obtained during the routine preoperative blood sampling that is performed for every patient on the day of hospital admission, one day before surgery. No separate venipuncture, no additional test, no additional visit and no change to diagnosis, treatment or follow-up is involved. Serum interleukin-17A, measured before surgery, is the primary outcome measure. Additional Treg/Th17-related cytokines, the interleukin-17A to interleukin-10 ratio, and systemic inflammatory indices calculated from the same blood draw are secondary outcome measures. Participants are assigned to the differentiated thyroid cancer group or the benign nodular goiter group after surgery, on the basis of the final histopathology report.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 25, 2026
Actual (reported)October 30, 2026
Actual (reported)November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Preoperative serum interleukin-17A concentration
Serum interleukin-17A concentration measured by ELISA in a blood sample obtained before surgery, compared between participants with differentiated thyroid carcinoma and participants with benign nodular goiter on final histopathology.
Single preoperative measurement, on the day of hospital admission
Preoperative serum concentrations of other Treg/Th17-related cytokines (interleukin-10, total transforming growth factor beta 1, interferon gamma, tumour necrosis factor alpha, interleukin-6)
Single preoperative measurement, on the day of hospital admission
Preoperative serum interleukin-17A to interleukin-10 ratio
Participants undergoing elective thyroidectomy whose final histopathology shows differentiated thyroid carcinoma of papillary, follicular or oncocytic type.
Participants undergoing elective thyroidectomy for a euthyroid thyroid nodule or nodular goiter whose final histopathology is benign.
Consecutive adults scheduled for elective thyroidectomy for a thyroid nodule or nodular goiter in a single university hospital department of general surgery.
Marmara University School of Medicine Hospital, Department of General Surgery
Istanbul, 34854, Turkey (Türkiye)
Serum obtained in a single additional tube during routine preoperative blood sampling. Samples are stored frozen only until recruitment is complete and are then assayed in one batch. No serum biobank is established, samples are not retained for future unspecified analyses, coded samples are shared only with the collaborating laboratory that performs the assays and with no other party, and remaining aliquots are destroyed after the study analyses are complete.
Sevgi Kalkanlı Taş, Professor of Immunology, PhD
Saglik Bilimleri Universitesi
Muhammer Ergenç, MD
Marmara University
First Submitted
October 25, 2026
First Posted
October 30, 2026
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
August 31, 2027
Decision Aid Efficacy in Low Risk Thyroid Cancer
Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses
Single preoperative measurement, on the day of hospital admission
Preoperative systemic inflammatory indices (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index)
Single preoperative measurement, on the day of hospital admission
Association between preoperative serum cytokine profile and clinicopathological features (tumour size, multifocality, extrathyroidal extension, lymph node metastasis, TNM stage)
Final histopathology report, within 4 weeks after surgery
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 30, 2026
Record last verified: 2026-10
Individual participant data will not be shared.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: